Ittrium (90y) Kolloid Cis Bio International

Yttrium-90 citrate, the active ingredient in Ittrium (90y) Kolloid Cis Bio International, is a radiopharmaceutical presented as a sterile injectable solution for intraarticular use. It delivers localized beta radiation to the synovial membrane, providing treatment for rheumatoid arthritis, hemophilic arthropathy and chronic synovitis in patients who require radiation synovectomy.

GNH USA supplies Ittrium (90y) Kolloid Cis Bio International as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ittrium (Yttrium-90 citrate) is employed in radiation synovectomy to manage inflammatory joint conditions. - Rheumatoid arthritis: reduces synovial inflammation and joint pain, improving function. - Hemophilic arthropathy: ablates diseased synovium to decrease recurrent joint bleeding. - Chronic synovitis: provides localized radiation to control persistent synovial proliferation and pain.

Adverse reactions are generally related to the local administration of beta‑emitting radiation and the injection procedure.

Common Side Effects: - Joint pain or discomfort at the injection site - Transient swelling or effusion of the treated joint - Warmth or mild erythema around the injection area - Limited range of motion for a few days - Low‑grade fever or chills - Mild arthralgia in adjacent joints

Serious or Rare Side Effects: - Radiation‑induced cartilage or bone damage - Deep tissue necrosis or ulceration - Severe joint infection (septic arthritis) - Systemic radiation exposure leading to hematologic changes - Allergic or hypersensitivity reaction to the citrate carrier - Persistent, large joint effusion requiring surgical intervention

Prior to administration, clinicians should evaluate patient suitability and adhere to radiation safety protocols. - Contraindication: active joint infection or uncontrolled coagulopathy: defer treatment until resolved. - Pregnancy and lactation: avoid use due to unknown fetal and neonatal radiation risk. - Monitoring: assess joint response and systemic blood counts at regular intervals post‑injection. - Radiation protection: handle and dispose of the product according to local radiopharmacy guidelines. - Storage: Store at 2-8°C: keep refrigerated in original shielded vial, protect from light, do not freeze.

Yttrium-90 citrate may interact with other therapies that affect radiation response or joint health.

Major Interactions (Avoid): - Concurrent intra‑articular corticosteroids: may diminish radiopharmaceutical efficacy. - Systemic chemotherapy or radiotherapy: increases cumulative radiation toxicity. - Other radiopharmaceuticals: risk of additive radiation dose.

Moderate Interactions (Monitor Closely): - NSAIDs: can mask post‑procedure inflammation, requiring careful assessment. - Anticoagulants or antiplatelet agents: heightened risk of joint bleeding after injection. - Disease‑modifying antirheumatic drugs (DMARDs): monitor for altered joint response.